Sector
PharmaceuticalsOpen
₹1,933.4Prev. Close
₹1,922.1Turnover(Lac.)
₹30,206.17Day's High
₹1,965.5Day's Low
₹1,906.952 Week's High
₹2,402.952 Week's Low
₹1,760.25Book Value
₹538.11Face Value
₹2Mkt Cap (₹ Cr.)
87,424.6P/E
21.65EPS
88.38Divi. Yield
0.6329 Apr 2025
12:00 AM
Board Meeting
Agenda : Audited Result
9 Jul 2024
12:00 AM
AGM
Announcement Date: 09 Jul, 2024
6 May 2024
12:00 AM
Dividend
Dividend Amount: 8
Record Date: 16 Jul, 2024
This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated in India.
Here are some of the stocks that may see significant price movement today: Godrej Properties, SBI Cards, Hyudai India, etc.
The tablets will be made at the company’s Goa facility, a site that has previously cleared global regulatory inspections and supports Lupin’s key exports.
The company said this deal fits into its larger strategy of expanding respiratory therapies beyond its home markets.
StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin America.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 91.22 | 91 | 90.9 | 90.79 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 20,511.87 | 18,320.86 | 18,059.29 | 18,474.78 |
Net Worth | 20,603.09 | 18,411.86 | 18,150.19 | 18,565.57 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 11,771.67 | 11,055.93 | 11,025.66 | 10,080.58 |
yoy growth (%) | 6.47 | 0.27 | 9.37 | -20.16 |
Raw materials | -4,467.26 | -4,182.31 | -4,207.27 | -3,474.35 |
As % of sales | 37.94 | 37.82 | 38.15 | 34.46 |
Employee costs | -1,918.16 | -1,695.86 | -1,703.22 | -1,441.64 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | -161.53 | 1,629.7 | 1,811.46 | 1,793.93 |
Depreciation | -514.19 | -502.83 | -518.75 | -389.81 |
Tax paid | -27.17 | -371.08 | -324.7 | -449.27 |
Working capital | -135.75 | -894.67 | -203.16 | 1,003.92 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 6.47 | 0.27 | 9.37 | -20.16 |
Op profit growth | -89.76 | 7.15 | -8.54 | -53.5 |
EBIT growth | -105.27 | -10.39 | 2.01 | -56.58 |
Net profit growth | -114.99 | 72.99 | -45.89 | -57.19 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 22,192.11 | 19,656.34 | 16,269.98 | 16,192.79 | 14,926.99 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 22,192.11 | 19,656.34 | 16,269.98 | 16,192.79 | 14,926.99 |
Other Operating Income | 515.79 | 354.48 | 371.68 | 212.69 | 235.97 |
Other Income | 195.82 | 120.17 | 73.36 | 142.05 | 137.62 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,672.5 | 93.87 | 4,01,372.75 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,938 | 83.3 | 1,84,017.51 | 667 | 0.43 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,488.3 | 24.97 | 1,20,199.04 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,322.4 | 59.44 | 1,12,475.6 | 474 | 0.18 | 2,385 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,283.8 | 19.91 | 1,07,151.95 | 1,200.7 | 0.62 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
M D Gupta
Managing Director
Nilesh Deshbandhu Gupta.
Director & Chief Executive Off
Vinita Gupta
Company Sec. & Compli. Officer
R V Satam
Independent Director
Jean-Luc Belingard
Executive Director & CFO
Ramesh Swaminathan
Independent Director
Mark D McDade
Independent Director
K B S Anand
Independent Director
Punita Kumar Sinha
Independent Director
Jeffrey Kindler
Independent Director
Alfonso Zulueta
Kalpataru Inspire 3rd Floor,
Off Western Exp HW Santacruz-E,
Maharashtra - 400055
Tel: 91-22-6640 2323
Website: https://www.lupin.com/
Email: investorservices@lupinpharma.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ing...
Read More
Reports by Lupin Ltd
What is the Lupin Ltd share price today?
What is the Market Cap of Lupin Ltd?
What is the PE and PB ratio of Lupin Ltd?
What is the 52 Week High and Low of Lupin Ltd?
What is the CAGR of Lupin Ltd?
What is the shareholding pattern of Lupin Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
